Rani Therapeutics Holdings, Inc. (RANI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Mir A. Imran | Executive Chairman | 40k | -- | 1957 |
| Mr. Talat Imran | CEO & Director | 105.82k | -- | 1982 |
| Mr. Svai S. Sanford | Chief Financial Officer | 416k | -- | 1970 |
| Dr. Mir Hashim | Chief Scientific Officer | 416k | -- | 1960 |
| Mr. Alireza Javadi | Vice President of Technical Operations | -- | -- | -- |
| Ms. Bella Vazquez | Vice President of Human Resources | -- | -- | -- |
| Ms. Kate McKinley M.B.A. | Chief Business Officer | -- | -- | 1977 |
Rani Therapeutics Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 105
Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Corporate Governance
Upcoming Events
May 13, 2025 at 8:05 PM UTC
Rani Therapeutics Holdings, Inc. Earnings Date